All In Biotech

Drug Trial Radar · NCT05797831

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

268

Planned (sponsor's estimate)

Start

Jul 17, 2023

Primary completion

Aug 2025

Study completion Jul 2027

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.

Conditions

  • Endometrial Cancer

Interventions

  • NavtemadlinDrug

    Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

  • Navtemadlin PlaceboDrug

    Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: To determine the navtemadlin Phase 3 doseTime frame: 12 months
  2. Part 2: To compare progression-free (PFS) survival by independent review committee (IRC) between navtemadlin and placeboTime frame: 50 months

Locations

83 sites in 17 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente Center

    Vallejo, California · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • St. Joseph

    Savannah, Georgia · Recruiting

  • Dr. Sudarshan K. Sharma, Ltd.

    Hinsdale, Illinois · Recruiting

  • Parkview Research Center

    Fort Wayne, Indiana · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Maryland Oncology Hematology, P.A.

    Silver Spring, Maryland · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada · Recruiting

  • Good Samaritan Hospital Medical Center

    West Islip, New York · Recruiting

  • FirstHealth Carolinas

    Pinehurst, North Carolina · Recruiting

  • OhioHealth Institute

    Columbus, Ohio · Recruiting

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma · Recruiting

  • Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • Northwest Cancer Specialists

    Portland, Oregon · Recruiting

  • Texas Oncology-Austin Central

    Austin, Texas · Recruiting

  • Texas Oncology-Fort Worth Cancer Center

    Fort Worth, Texas · Recruiting

  • Texas Oncology-San Antonio Medical Center

    San Antonio, Texas · Recruiting

  • University Hospital Graz, Department of Gynecology and Obstetrics

    Graz, Austria · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • Cross Cancer Institute

    Edmonton, Canada · Recruiting

  • CHUM - University of Montreal Hospital Centre

    Montreal, Canada · Recruiting

  • Odense University Hospital

    Odense, Denmark · Recruiting

  • Tartu University Hospital

    Tartu, Estonia · Recruiting

  • Kuopio University Hospital

    Kuopio, Finland · Recruiting

  • Turku University Hospital

    Turku, Finland · Recruiting

  • LTD High Technology hospital Medcenter

    Batumi, Georgia · Recruiting

  • American Hospital Network LLC

    Tbilisi, Georgia · Recruiting

  • Caucasus Medical Centre

    Tbilisi, Georgia · Recruiting

  • National Institute of Oncology

    Budapest, Hungary · Recruiting

  • University of Debrecen Clinical Center

    Debrecen, Hungary · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • A.O. Cannizzaro

    Catania, Italy · Recruiting

  • IRCCS Istituto Romangolo per lo Studio dei Tumori "Dino Amadori"

    Forlì, Italy · Recruiting

  • Ospedale Policlinico San Martino

    Genoa, Italy · Recruiting

  • ASST di Lecco-Ospedale Alessandro Manzoni

    Lecco, Italy · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.